Man Group PLC Cerevel Therapeutics Holdings, Inc. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $24.9 Million - $27.4 Million	-640,275 Reduced 65.5%	337,271 $13.8 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $36.2 Million - $38.3 Million	885,686 Added 964.17%	977,546 $41.3 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $1.86 Million - $3.9 Million	91,860 New	91,860 $3.89 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $3.64 Million - $5.38 Million	152,117 New	152,117 $4.84 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $250,512 - $451,335	12,149 New	12,149 $321,000
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $169,158 - $399,864	-13,468 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $166,599 - $238,922	13,468 New	13,468 $185,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.